Bufo toads — specifically Incilius alvarius, the Sonoran Desert toad — produce a venom that contains 5-MeO-DMT at 15–25% concentration by dry weight. Estimates place the number of people seeking this medicine annually at 30,000 to 100,000 globally. Wild populations cannot absorb that scale of demand. This is not primarily a pharmacological question anymore. It is a conservation question, and the answer changes what responsible practice looks like.
In short: Incilius alvarius is a large toad native to the Sonoran Desert whose parotoid glands secrete venom containing 5-MeO-DMT at 15–25% by dry weight. Ceremonial demand has grown faster than wild populations can sustain. Laboratory-synthesized 5-MeO-DMT is molecularly identical to the toad-derived compound — same molecule, no toad required. Responsible providers use synthetic. At Transcend, 5-MeO-DMT ceremony costs $600–$1,500 CAD and uses synthetic medicine only.
What Incilius alvarius Is
Incilius alvarius — formerly classified as Bufo alvarius, which is where the common name comes from — is the largest native toad in the United States. Adults reach 7.5 inches in length and can weigh over 200 grams. The range covers the Sonoran Desert: southern Arizona, a narrow strip of southeastern California, and the Mexican states of Sonora and Sinaloa.
The toad is not present year-round. It spends approximately 9–10 months underground, emerging only after summer monsoon rains to breed in temporary pools and permanent water sources. The active surface window is narrow — roughly July through September in most of the range. Outside that window, the animal is inaccessible.
The parotoid glands are the relevant anatomy. These are large, kidney-shaped structures positioned behind the eyes and on the shoulders. When the toad is stressed or handled, the glands secrete a white, viscous venom. This is not the cane toad (Rhinella marina), which is invasive across much of Australia and North America. Different animal, different chemistry, different conservation status.
What the Venom Contains
5-MeO-DMT makes up 15–25% of the toad's dried venom — a concentration found in no other animal source. When vaporized and inhaled, the compound reaches the brain in seconds.
The mechanism is primarily 5-HT1A receptor agonism. This is what distinguishes 5-MeO-DMT from DMT (N,N-DMT), which acts at 5-HT2A receptors and produces the complex visual content most people associate with psychedelics. 5-MeO-DMT does not produce that. What it produces instead is rapid, complete dissolution of the sense of self — what participants consistently describe as an absence of bounded identity, a merger with surroundings, and occasionally something they later struggle to name at all. Active duration is 20–45 minutes. Re-entry into ordinary consciousness is gradual over the following 15–20 minutes.
The venom also contains bufotenin and other tryptamine compounds. Whether these produce meaningful additional pharmacological effects is debated among practitioners. The primary psychoactive compound is 5-MeO-DMT.
How Ceremonial Use Developed
This history is not ancient. In 1983, a researcher writing under the name Albert Most published a pamphlet describing how to collect venom from Incilius alvarius, dry it, and smoke it. That is where ceremonial use of this toad's venom began. There is no pre-Columbian tradition of using this compound in ceremony — a fact that indigenous scholars and communities in the Sonoran region have raised explicitly as ceremonial demand has grown and acquired spiritual framing it did not originate with.
The Yoeme and Yaqui peoples, who are native to the toad's range in Sonora, have publicly objected to their geography and identity being used as context for a practice with no roots in their traditions. Ceremonial language that frames bufo ceremonies as an ancient indigenous spiritual practice is not historically accurate.
By the early 2020s, estimates placed global ceremonial participation at 30,000 to 100,000 people per year. The majority of those ceremonies used wild-collected venom.
The Conservation Problem
Incilius alvariusis not currently listed as endangered by the IUCN. It is listed as a protected species under Mexico's NOM-059-SEMARNAT-2010 wildlife protection legislation, which means commercial collection and trade within Mexico requires permits that most ceremonial providers operating informally do not hold. In California, collecting or possessing the toad is prohibited by state law. In Arizona, a fishing licence is required. These protections have not stopped collection.
The biology of the species works against it. The breeding window is 6–8 weeks per year. Population recovery from localised depletion is slow. Repeated handling and venom milking stresses the animals — collected individuals show reduced survival rates compared to undisturbed populations. The narrow seasonal window concentrates collecting pressure on the same accessible individuals year after year.
Herpetologists affiliated with the Society for the Study of Amphibians and Reptiles and other conservation bodies have documented collection pressure in accessible areas of Sonora and southern Arizona since the early 2010s. The demand that 30,000 to 100,000 annual ceremonies represents is not compatible with stable wild populations in accessible habitat. Remote terrain provides some buffer. It is not a solution.
Synthetic 5-MeO-DMT — Same Molecule, No Toad Required
5-MeO-DMT can be synthesized in a laboratory. The molecule is not patented. The synthesis is not complex at pharmaceutical grade. The compound that reaches the brain when someone inhales synthetic 5-MeO-DMT is molecularly identical to the compound in toad venom — same structure, same receptor affinity, same pharmacological action.
Research supports this equivalence. A study by Uthaug et al. published in Psychopharmacology followed participants who received 5-MeO-DMT in naturalistic ceremonial settings using both toad-derived and synthetic sources. No significant differences in subjective effects or reported outcomes were identified between the two. This finding is consistent with what the pharmacology predicts: the active molecule is the same.
Any provider still using toad-derived venom when laboratory-synthesized 5-MeO-DMT is available is not making a pharmacological choice — the molecule is identical, and the conservation cost is not.
Some providers use “natural” framing to justify toad-derived medicine. This is a marketing position, not a therapeutic one. Synthetic does not mean inferior. It means the toad stays in the desert.
What a 5-MeO-DMT Ceremony Involves
A 5-MeO-DMT ceremony is not long. The active period is 20–45 minutes. What happens in that window is not proportional to its duration — this is one of the most immediately overwhelming experiences available in any clinical or ceremonial setting.
Medical screening precedes any confirmed ceremony date. The screening covers medications, psychiatric history, cardiovascular health, and current mental state. What the screening assesses and what it rules out is covered in the post on the bufo ceremony experience. For people considering both 5-MeO-DMT and ibogaine as part of a longer process, the post on ibogaine and 5-MeO-DMT covers how sequencing works and what the evidence supports.
At Transcend, 5-MeO-DMT ceremony costs $600–$1,500 CAD and uses synthetic medicine only. Preparation and integration are part of the programme — not optional additions. Integration after 5-MeO-DMT is different from integration after ibogaine. Ibogaine produces detailed biographical content — memories, patterns, events — that can be examined explicitly. 5-MeO-DMT produces no narrative content. Integration consists of holding what happened as it slowly becomes something language can approach. This is not easier than ibogaine integration. It is different in kind.
Who Should Not Pursue This
SSRIs and SNRIs are absolute contraindications. The risk of serotonin syndrome is real and potentially fatal. There are no exceptions. Someone on an SSRI who wants to pursue 5-MeO-DMT ceremony must complete a medically supervised taper first — a process that takes weeks to months depending on the medication. No ceremony is confirmed before that process is complete.
Active psychosis and schizophrenia spectrum disorder are also absolute contraindications. 5-MeO-DMT produces complete ego dissolution. Entering that state with an already-disrupted sense of reality does not produce stability.
Someone in acute psychiatric crisis is not an appropriate candidate — regardless of how urgently they believe they need this work. The medicine amplifies what is present. It does not resolve a crisis by delivering an experience.
There is a pattern that appears in intake conversations: someone who has spent months researching 5-MeO-DMT, has decided this is the answer, and arrives certain they have found the solution. The medicine is not interested in what someone has decided. It shows people what is present — not what they are hoping to find. When what is present is acute need being managed by conviction about the cure, ceremony is the wrong next step. These conversations happen directly at Transcend. If the answer is not yet, that is what you will be told — directly and without softening it. Information on the application process is on the bufo retreat page. The conversation starts at the application.
Frequently Asked Questions
What are bufo toads?
Bufo toads — more precisely Incilius alvarius, the Sonoran Desert toad — are a large toad species native to the Sonoran Desert of Arizona and northern Mexico. Their parotoid glands secrete a venom containing 5-MeO-DMT at 15–25% by dry weight, a concentration found in no other animal source. The name “bufo” reflects the toad's former genus classification (Bufo), since revised to Incilius.
Are bufo toads endangered?
Incilius alvariusis not listed as endangered on the IUCN Red List. It is listed as a protected species under Mexico's NOM-059-SEMARNAT-2010 wildlife protection legislation. In California, collection and possession of the toad is prohibited by state law. The species faces documented collection pressure from ceremonial demand — its breeding window of 6–8 weeks per year and slow reproductive rate make wild populations slow to recover from localised depletion.
Is bufo toad venom different from synthetic 5-MeO-DMT?
The primary active compound — 5-methoxy-N,N-dimethyltryptamine — is molecularly identical in both. Outcome research comparing toad-derived and synthetic 5-MeO-DMT found no significant differences in subjective effects or reported outcomes. Toad venom also contains bufotenin and other tryptamine compounds, but the primary psychoactive agent is 5-MeO-DMT, and its pharmacological action is the same regardless of source.
Why do responsible providers use synthetic 5-MeO-DMT?
Because the pharmacology is identical and wild Incilius alvariuspopulations are under collection pressure they cannot absorb at current ceremonial volumes. Using toad-derived venom when synthetic is available carries a real conservation cost with no corresponding therapeutic benefit. The molecule reaching the participant's brain is the same either way.
How does 5-MeO-DMT compare to DMT?
They are structurally related but act through different receptors and produce different experiences. DMT acts at 5-HT2A receptors and produces complex visual content — geometric patterns, entities, narrative landscapes. 5-MeO-DMT acts primarily at 5-HT1A receptors and produces complete ego dissolution without visual content. 5-MeO-DMT is active for 20–45 minutes; smoked DMT for 15–20 minutes. They are not comparable on a single scale. Different in kind.
What does a 5-MeO-DMT ceremony involve?
Medical screening first — covering medications (SSRIs and SNRIs are absolute contraindications), psychiatric history, cardiovascular health, and current mental state. The active ceremony lasts 20–45 minutes. Preparation and integration are part of the programme. At Transcend, ceremony costs $600–$1,500 CAD and uses synthetic 5-MeO-DMT only. Candidacy is established through screening before any payment is taken.
Who is not a candidate for 5-MeO-DMT ceremony?
Current SSRIs or SNRIs without a completed medically supervised taper — serotonin syndrome risk is real and potentially fatal, no exceptions. Active psychosis or schizophrenia spectrum disorder. Acute psychiatric crisis. Significant cardiovascular conditions including uncontrolled hypertension and arrhythmia. MAOIs or ayahuasca within the preceding 4 weeks. Pregnancy. Someone primarily seeking a mystical experience or who is in crisis and has decided ceremony is the solution is also not an appropriate candidate at this time.
Sources
Uthaug MV, Lancelotta R, van Oorsouw K, et al. “A single inhalation of vapor from dried toad secretion containing 5-MeO-DMT in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms.” Psychopharmacology (2019). doi:10.1007/s00213-019-05236-w · Society for the Study of Amphibians and Reptiles